BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Cerilliant
Farmers Insurance
Deloitte
Chinese Patent Office
Johnson and Johnson
Mallinckrodt
Moodys
Covington
Baxter

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: RE45198

« Back to Dashboard

Which drugs does patent RE45198 protect, and when does it expire?

Patent RE45198 protects ZEGERID and is included in one NDA.

This patent has sixty patent family members in twenty-three countries.
Summary for Patent: RE45198
Title:Omeprazole solution and method for using same
Abstract: A pharmaceutical composition includes an aqueous solution/suspension of omeprazole or other substituted benzimidazoles and derivatives thereof in a pharmaceutically acceptable carrier comprising a bicarbonate salt of a Group IA metal. A method for treating and/or preventing gastrointestinal conditions by administering to a patient a pharmaceutical composition including an aqueous solution/suspension of omeprazole or other substituted benzimidazoles and derivatives thereof in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal wherein the administering step consists of a single dosage form without requiring further administering of the bicarbonate salt of the Group IA metal. A pharmaceutical composition for making a solution/suspension of omeprazole or other substituted benzimidazoles and derivatives thereof includes omeprazole or other substituted benzimidazoles and derivatives thereof and a bicarbonate salt of a Group IA metal in a form for convenient storage whereby when the composition is dissolved in aqueous solution, the resulting solution is suitable for enteral administration.
Inventor(s): Phillips; Jeffrey O. (Ashland, MO)
Assignee: The Curators of The University Of Missouri (Columbia, MO)
Application Number:11/960,934
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent RE45198

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Santarus Inc ZEGERID omeprazole; sodium bicarbonate FOR SUSPENSION;ORAL 021636-001 Jun 15, 2004 AB RX Yes No ➤ Subscribe ➤ Subscribe SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS ➤ Subscribe
Santarus Inc ZEGERID omeprazole; sodium bicarbonate FOR SUSPENSION;ORAL 021636-002 Dec 21, 2004 AB RX Yes Yes ➤ Subscribe ➤ Subscribe REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS ➤ Subscribe
Santarus Inc ZEGERID omeprazole; sodium bicarbonate FOR SUSPENSION;ORAL 021636-002 Dec 21, 2004 AB RX Yes Yes ➤ Subscribe ➤ Subscribe SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent RE45198

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,780,882 Substituted benzimidazole dosage forms and method of using same ➤ Subscribe
5,840,737 Omeprazole solution and method for using same ➤ Subscribe
6,489,346 Substituted benzimidazole dosage forms and method of using same ➤ Subscribe
7,399,772 Substituted benzimidazole dosage forms and method of using same ➤ Subscribe
6,699,885 Substituted benzimidazole dosage forms and methods of using same ➤ Subscribe
6,645,988 Substituted benzimidazole dosage forms and method of using same ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent RE45198

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Mexico PA04006912 ➤ Subscribe
Norway 20023313 ➤ Subscribe
Japan 2012136531 ➤ Subscribe
Mexico PA04000223 ➤ Subscribe
Mexico PA02006780 ➤ Subscribe
South Korea 20040099265 ➤ Subscribe
South Korea 20040047771 ➤ Subscribe
Japan 2005519901 ➤ Subscribe
Japan 2004521955 ➤ Subscribe
Japan 2003519656 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
US Department of Justice
Cipla
Cantor Fitzgerald
Novartis
Moodys
Boehringer Ingelheim
AstraZeneca
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot